Home / Trending / The Science of Misleading Claims: FDA Enforcement and the Proprietary Blend Loophole (Part 2 of 3)

Trending

The Science of Misleading Claims: FDA Enforcement and the Proprietary Blend Loophole (Part 2 of 3)

October 14, 2026

The Science of Misleading Claims: FDA Enforcement and the Proprietary Blend Loophole

Opening Question

When a dietary supplement manufacturer markets a marine lipid capsule as a clinical solution for chronic inflammatory pathology while concealing the exact milligram dosage of active fatty acids behind a “proprietary blend” label, does statutory compliance with general food labeling exemptions insulate the vendor, or does the combination of information asymmetry, unapproved disease claims, and mismatched generic research trigger regulatory enforcement and consumer fraud liability?

Direct Answer Paragraph

The invocation of statutory “proprietary blend” labeling exemptions affords absolutely no immunity against deceptive marketing or unapproved drug enforcement. Relying upon Herbert Broom’s foundational legal maxim dolus versatur in generalibus (fraud lurks in generalities), regulatory authorities and superior courts dictate that obscuring sub-therapeutic ingredient dosages behind generalized blend weights—while simultaneously deploying “borrowed science” and implied disease-mitigation claims—violates the Federal Food, Drug, and Cosmetic Act, the Competition Act, and the Food and Drugs Act, rendering the marketing architecture an actionable statutory breach.

Foundational Post

To protect corporate assets and properly evaluate the legal boundaries of digital commerce and regulatory compliance, refer to our foundational analysis here: https://lawcap.ca/smart-legislation-law-for-a-digital-age/

Overview

Part 1 of this treatise deconstructed the front-end persuasive apparatus of the Omega XL campaign, illustrating how daytime television infomercials, celebrity authority transfers, and first-responder testimonials intersect with Federal Trade Commission (FTC) endorsement guidelines and Section 74.01(1)(b) of the Canadian Competition Act.

Part 2 moves from the broadcast studio into the forensic laboratory and the statutory labeling matrix. When a consumer protection litigator or regulatory investigator audits a high-margin nutraceutical product, the central evidentiary inquiry focuses on Biochemical Candour versus Information Asymmetry: what is actually inside the capsule, in what exact milligram quantity, and does that specific dosage match the clinical literature cited in the advertisement?

In the North American dietary supplement marketplace, manufacturers routinely justify charging a $300\%$ to $500\%$ price premium over generic equivalents by asserting that their product contains a unique, hyper-concentrated formulation supported by decades of published medical research. However, forensic decompilation of these campaigns frequently exposes a three-part regulatory and evidentiary vulnerability:

The Proprietary Blend Shield: Utilizing statutory labeling carve-outs to group active marine extracts with inexpensive carrier oils (such as olive oil) under a single aggregate weight, preventing consumers and physicians from seeing the exact milligram dosage of active Eicosapentaenoic Acid ($\text{EPA}$) and Docosahexaenoic Acid ($\text{DHA}$).
The Disease-Claim Boundary Breach: Crossing the strict statutory line separating permissible “structure/function” claims (e.g., “supports joint health”) from illegal, unapproved “disease/therapeutic” claims (e.g., “eliminates arthritic inflammation and replaces prescription pain medications”).
The “Borrowed Science” Fallacy: Citing “40 years of clinical research” conducted on massive dosages of raw ingredients or entirely different chemical extractions to claim clinical validation for a microscopic, untested retail capsule.

Part 2 establishes the forensic, regulatory, and evidentiary framework required to pierce proprietary blend disclosures, analyze FDA Warning Letters, and dismantle unsubstantiated scientific representations in complex consumer class actions.

The Proprietary Blend as an Information Asymmetry Tool

In classical contract and consumer protection law, a fair market transaction requires symmetrical access to material facts. Within the United States regulatory regime—governed by the Dietary Supplement Health and Education Act of 1994 (DSHEA) and codified at 21 C.F.R. § 101.36(c)—manufacturers are permitted a significant statutory concession known as the “Proprietary Blend” exemption.

Under 21 C.F.R. § 101.36(c), rather than listing the exact quantitative milligram weight of each individual dietary ingredient on the Supplement Facts panel, a manufacturer may group multiple ingredients into a “Proprietary Blend” (or “Proprietary Complex”). The manufacturer is legally required to disclose only:

The aggregate total weight of the entire blend; and
The constituent ingredients listed in descending order of predominance by weight.

While originally intended by Congress to protect legitimate trade secrets and prevent immediate formula cloning by competitors, the proprietary blend mechanism is frequently weaponized in direct-to-consumer supplement marketing to engineer profound information asymmetry:

The Carrier Oil Dilution Dynamic: If a supplement label discloses a “$300\text{ mg}$ Proprietary Blend” containing green-lipped mussel extract (Perna canaliculus), extra virgin olive oil, and d-alpha-tocopherol (Vitamin E), the consumer is left completely blind as to the ratio. Because ingredients are listed in descending order, the active mussel extract could constitute $151\text{ mg}$ while the inexpensive olive oil filler constitutes $148\text{ mg}$—or the active lipid fraction could be a mere fraction of the capsule’s total payload.
The Sub-Therapeutic EPA/DHA Discrepancy: In clinical rheumatology and nutritional biochemistry, achieving a measurable anti-inflammatory response via marine omega-3 fatty acids typically requires a daily therapeutic intake of $2,000\text{ mg}$ to $4,000\text{ mg}$ of combined $\text{EPA}$ and $\text{DHA}$. A standard, inexpensive commercial fish oil softgel ($1,000\text{ mg}$ to $1,200\text{ mg}$ total weight) transparently discloses $300\text{ mg}$ to $700\text{ mg}$ of combined $\text{EPA}$ and $\text{DHA}$ per pill for pennies per dose. Conversely, a miniature marine lipid capsule with a total payload under $300\text{ mg}$ physically cannot contain gram-level quantities of $\text{EPA}$ and $\text{DHA}$. By hiding behind a proprietary blend label and claiming the extract is “22 times more potent than regular fish oil,” the marketer obscures the tiny absolute milligram quantity of active omega-3s, neutralizing the consumer’s ability to perform a rational cost-per-milligram comparison.
The Cross-Border Contrast (Health Canada NHP Mandate): This U.S. labeling loophole contrasts sharply with Canada’s Natural Health Products Regulations (SOR/2003-196). To obtain a Natural Product Number (NPN) from Health Canada, a manufacturer must disclose the exact quantitative amount of each medicinal ingredient per dosage unit on the product label, while non-medicinal carrier oils (like olive oil) must be segregated and listed separately as non-medicinal excipients. In cross-border litigation, plaintiffs’ counsel routinely subpoena Canadian NPN regulatory filings and Certificates of Analysis (CoAs) to expose the exact milligram breakdown obscured on U.S. proprietary blend labels.

Analyzing FDA Warning Letters and Deceptive Disease Claims

Both the United States Food and Drug Administration (FDA)—enforcing the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §§ 321, 355—and Health Canada—enforcing the Food and Drugs Act, R.S.C. 1985, c. F-27—maintain an unyielding statutory wall between dietary supplements and pharmaceutical drugs.

Under 21 U.S.C. § 343(r)(6), a dietary supplement manufacturer is strictly limited to making Structure/Function Claims: statements describing the role of a nutrient or dietary ingredient intended to affect the normal structure or function in humans (e.g., “promotes healthy joint function” or “supports mobility in healthy aging adults”).

The moment an advertiser represents—expressly or by implication—that a supplement is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease (21 U.S.C. § 321(g)(1)(B)), the product is legally reclassified as an Unapproved New Drug. Selling an unapproved new drug in interstate commerce without an FDA-approved New Drug Application (NDA) is a strict-liability statutory violation.

A forensic review of FDA Warning Letters issued across the supplement sector—including regulatory scrutiny directed at Great HealthWorks, Inc.—reveals the precise mechanisms by which marketers trigger federal enforcement:

Implied Disease Claims via Symptomatology: Advertisers attempt to evade the word “arthritis” or “osteoarthritis” by focusing on severe clinical symptoms: “chronic joint pain,” “bone-on-bone inflammation,” “morning stiffness,” and “swollen knuckles.” Regulatory tribunals and the FDA dictate that claiming to resolve the signature pathology of a chronic disease is legally indistinguishable from claiming to treat the disease itself.
The Testimonial Backdoor: In Warning Letters, the FDA routinely cites consumer testimonials embedded on company websites, social media pages, and video broadcasts. When a customer testimonial states, “I had severe osteoarthritis in both knees and couldn’t walk up stairs until I took this product,” or “I threw away my prescription NSAIDs and painkillers,” the FDA treats that consumer quote as an official promotional labeling claim made by the manufacturer.
Meta-Tags, URLs, and Digital Architecture: FDA investigators do not restrict their review to the physical bottle label. Under 21 U.S.C. § 321(m), “labeling” encompasses all written, printed, or graphic matter accompanying an article. Warning letters routinely cite hidden website meta-descriptions, search engine marketing keywords, and hyperlinked scientific articles targeting arthritis, fibromyalgia, and inflammatory bowel disease as conclusive proof of intended therapeutic use.

Evidentiary Thresholds: What Constitutes “40 Years of Research”?

A ubiquitous trope in dietary supplement advertising is the appeal to historical academic volume—asserting that a product or its “proprietary extract” is “backed by over 40 years of clinical research and dozens of published studies.”

In forensic legal analysis under Section 74.01(1)(b) of the Canadian Competition Act and FTC substantiation doctrine, this claim frequently unmasks the fallacy of “Borrowed Science” (Structural Misrepresentation). When corporate counsel is compelled during litigation discovery to produce the “40 years of research” relied upon prior to broadcasting the claim, forensic expert witnesses (R. v. Mohan / Daubert) audit the dossier across four fatal methodological gaps:

Ingredient Identity Mismatch (Raw Powder vs. Lipid Extract): Much of the early academic literature from the 1970s and 1980s evaluated freeze-dried, whole New Zealand green-lipped mussel powder—which contains proteins, complex carbohydrates (glycosaminoglycans), and minerals—rather than a supercritical $\text{CO}_2$ or chemically stabilized lipid-only oil extract. A manufacturer cannot cite studies on whole mussel powder to substantiate a lipid-only capsule that lacks the protein and glycosaminoglycan fractions.
Dosage Discrepancy (The Milligram Chasm): If published human clinical trials demonstrating a statistically significant reduction in joint tenderness ($p < 0.05$) administered $1,200\text{ mg}$ to $3,000\text{ mg}$ per day of pure marine extract, a vendor cannot legally cite those studies to substantiate a commercial product that delivers only $100\text{ mg}$ to $300\text{ mg}$ per serving. In pharmacology, the dose makes the medicine; sub-therapeutic micro-dosing renders the cited high-dose literature scientifically irrelevant.
Animal and In Vitro Extrapolation: Supplement dossiers routinely pad their study counts with in vitro (petri dish cell culture) experiments or veterinary studies conducted on arthritic dogs and horses. Both the FTC and Canadian superior courts (Canada (Competition Bureau) v. Chatr Wireless) maintain that animal and in vitro observations cannot substantiate human clinical efficacy claims.
Uncontrolled, Open-Label, or Industry-Funded Flaws: Studies that lack a placebo control group, fail to implement double-blinding, rely on tiny sample sizes ($n < 30$), or exhibit un-replicated statistical p-hacking fail the threshold of “competent and reliable scientific evidence.”

When a marketer aggregates forty years of disparate, third-party academic papers on generic marine lipids and presents them to the public as direct clinical validation of its own specific, proprietary retail capsule, the representation constitutes an actionable statutory falsehood.

Legal Domain Identification

Food and Drug Regulatory Law (U.S. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 321, 343, 355; Dietary Supplement Health and Education Act [DSHEA], 21 C.F.R. § 101.36; Canadian Food and Drugs Act, R.S.C. 1985, c. F-27; Natural Health Products Regulations, SOR/2003-196), Consumer Protection and Competition Law (Competition Act, R.S.C. 1985, c. C-34, ss. 52, 74.01; Federal Trade Commission Act, 15 U.S.C. §§ 45, 52), Evidence Law (Expert Scientific Admissibility under Daubert and R. v. Mohan), and the Doctrine of Nullity.

The Supplement Formulation & Regulatory Substantiation Matrix

Regulatory agencies and superior courts evaluate supplement labeling, proprietary blends, and scientific substantiation through an objective forensic matrix:

                  ┌─────────────────────────────────────────────────────────┐
                  │       SUPPLEMENT FORMULATION & SUBSTANTIATION AUDIT     │
                  │       (FDA 21 C.F.R. § 101.36 / COMPETITION ACT)        │
                  └────────────────────────────┬────────────────────────────┘
                                               │
                                               ▼
                  ┌─────────────────────────────────────────────────────────┐
                  │    STEP 1: DECOMPILE THE LABEL & PROPRIETARY BLEND      │
                  │   • Extract Certificate of Analysis (CoA) & NPN filings │
                  │   • Isolate exact mg of active extract vs. olive oil    │
                  │   • Quantify absolute mg of active EPA / DHA per dose   │
                  └────────────────────────────┬────────────────────────────┘
                                               │
                                               ▼
                  ┌─────────────────────────────────────────────────────────┐
                  │    STEP 2: THE DISEASE VS. STRUCTURE/FUNCTION GATE      │
                  │   Does marketing / testimonial copy claim to treat,     │
                  │   mitigate, or cure chronic inflammatory pathology?     │
                  └────────────────────────────┬────────────────────────────┘
                                               │
           ┌───────────────────────────────────┴───────────────────────────────────┐
           ▼                                                                       ▼
 [ UNAPPROVED DISEASE CLAIMS DETECTED ]                                  [ PERMISSIBLE STRUCTURE/FUNCTION CLAIMS ]
 • Claims relief of chronic joint pain / arthritis                       • Limited to "helps support joint health"
 • Testimonials claim replacement of prescription NSAIDs                 • No implied treatment of arthritic disease
 • Trigger: Reclassified as Unapproved New Drug                          • Advance to Step 3: Substantiation Audit
           │                                                                       │
           ▼                                                                       ▼
 ┌─────────────────────────────────────────┐                             ┌─────────────────────────────────────────┐
 │   FDA / HEALTH CANADA ENFORCEMENT       │                             │   STEP 3: THE "BORROWED SCIENCE" AUDIT  │
 │ • Violates 21 U.S.C. §§ 321(g), 355(a)  │                             │   Do the cited "40 years of studies"    │
 │ • Violates Food and Drugs Act s. 3      │                             │   match the exact retail dose & extract?│
 │ • FDA Warning Letter & Injunction Issued│                             └────────────────────┬────────────────────┘
 └─────────────────────────────────────────┘                                                  │
                                                                         ┌────────────────────┴────────────────────┐
                                                                         ▼                                         ▼
                                                           [ MISMATCHED / GENERIC STUDIES ]          [ PRODUCT-SPECIFIC RDBPC TRIALS ]
                                                           • Studies used 3,000mg; pill has <300mg   • Human trials match exact retail dose
                                                           • Relies on dog/rat or in vitro studies   • Statistically significant ($p < 0.05$)
                                                           • Fails "Adequate & Proper Test" threshold• Transparently discloses active mg
                                                                         │                                         │
                                                                         ▼                                         ▼
                                                           ┌─────────────────────────────┐           ┌─────────────────────────────┐
                                                           │  STATUTORY FRAUD & LIABILITY│           │   REGULATORY SAFE HARBOR    │
                                                           │ • Breaches Competition Act  │           │ • Complies with FTC / Bureau│
                                                           │ • Class Action Certified    │           │ • Complies with NHP License │
                                                           └─────────────────────────────┘           └─────────────────────────────┘

The Complete 3-Part Series Index: The Omega XL Marketing & Regulatory Architecture

This comprehensive three-part legal and forensic treatise examines the regulatory, scientific, and transactional mechanics governing direct-to-consumer supplement campaigns across North American jurisdictions:

Part 1 of 3: Deconstructing the Omega XL Marketing Architecture: Legal Boundaries of Supplement Claims — Analyzing daytime television infomercial mechanics, FTC Endorsement Guides (16 C.F.R. Part 255), National Advertising Division (NAD) rulings on PCSO-524 “breakthrough” claims, and the Competition Act s. 74.01(1)(b) “adequate and proper test” threshold.
Part 2 of 3 (Current): The Science of Misleading Claims: FDA Enforcement and the Proprietary Blend Loophole — Examining the “proprietary blend” labeling loophole used to obscure active EPA/DHA dosages, FDA Warning Letters regarding unapproved disease claims, and the evidentiary fallacy of citing forty years of generic academic research to validate an under-dosed commercial capsule.
Part 3 of 3: Supplement Subscriptions and Dark Patterns: Legal Remediation for Auto-Ship Financial Traps — Formulating the litigation and consumer recovery manual against negative-option “dark patterns,” evaluating recurring credit card traps under the Restore Online Shoppers’ Confidence Act (ROSCA) and provincial consumer protection statutes, and executing chargeback and statutory cancellation protocols.

Key Requirements / Elements to Audit Supplement Formulation and Disease Claims

To legally evaluate whether a dietary supplement’s formulation and scientific marketing comply with federal statutory mandates—or to prosecute a deceptive marketing claim in superior court—counsel must establish:

The Piercing of the Proprietary Blend Veil: In litigation discovery, counsel must subpoena the manufacturer’s Master Manufacturing Records (MMRs), batch production logs, and third-party Certificates of Analysis (CoAs) to establish the exact milligram weight of the active marine extract versus the inert carrier oil (olive oil) inside the capsule.
The Identification of Implied Disease Claims: Under FDA guidance (21 C.F.R. § 101.93(g)) and Health Canada standards, counsel must audit the entirety of the marketing ecosystem—including video transcripts, consumer reviews selected for promotion, and website meta-tags—to prove that the vendor is marketing the product to mitigate or treat a recognizable disease state (such as osteoarthritis or chronic inflammatory pathology) without drug approval.
The Rejection of Non-Equivalent “Borrowed Science”: Under Section 74.01(1)(b) of the Competition Act and FTC substantiation law, counsel must demonstrate any biochemical or quantitative divergence between the commercial product and the academic literature cited in its ads. If the cited literature tested a different extraction method or a dosage five times higher than the retail instructions, the cited research is legally inadmissible as substantiation.
The Isolation of Active Omega-3 Equivalence: Forensic nutritionists must quantify the exact milligram payload of Eicosapentaenoic Acid ($\text{EPA}$), Docosahexaenoic Acid ($\text{DHA}$), and other furan or free fatty acids delivered per daily serving, contrasting that figure against established clinical efficacy thresholds ($\ge 2,000\text{ mg/day}$) and the cost of standard over-the-counter marine oils.

Examples / Application

A. The Proprietary Blend Carrier-Oil Discrepancy in Discovery

A dietary supplement marketer sells a miniature softgel capsule advertised as a “Super-Concentrated Marine Lipid Complex” for $65 per bottle. The Supplement Facts panel lists a “Proprietary Blend: $300\text{ mg}$” containing Green-Lipped Mussel Extract, Extra Virgin Olive Oil, and Vitamin E. The marketing copy claims two tiny capsules deliver more inflammation-fighting power than a handful of standard fish oil pills.

In a certified consumer class action alleging deceptive pricing and misrepresentation, plaintiffs’ counsel subpoenas the manufacturer’s batch formulation sheets and conducts Gas Chromatography-Mass Spectrometry (GC-MS) testing on the retail capsules.

The forensic testing reveals that of the $300\text{ mg}$ proprietary blend in each capsule, $245\text{ mg}$ consists of ordinary extra virgin olive oil, while only $50\text{ mg}$ consists of actual green-lipped mussel lipid extract, yielding less than $15\text{ mg}$ of combined $\text{EPA}$ and $\text{DHA}$. A standard $12 bottle of pharmacy fish oil delivers $600\text{ mg}$ of $\text{EPA/DHA}$ per capsule—forty times the active omega-3 payload.

The court rules that while listing the ingredients as a “proprietary blend” technically complied with the baseline formatting of 21 C.F.R. § 101.36(c), combining that label opacity with television advertisements claiming “concentrated superiority over fish oil” created a materially deceptive general impression (dolus versatur in generalibus). The proprietary blend exemption cannot be used as an instrument of fraud to mask the sale of overpriced olive oil.

B. The FDA Warning Letter Triggered by Website Testimonials

A nutraceutical enterprise carefully instructs its copywriters to use only compliant structure/function language on its physical bottle labels (“Supports Joint Mobility and Comfort”). However, on its e-commerce checkout page and official social media channels, the company curates and highlights dozens of verified customer video testimonials.

In the featured videos, customers make explicit statements: “My rheumatologist told me my rheumatoid arthritis required biologics, but after taking four pills a day, my C-reactive protein levels dropped and my arthritis is in remission,” and “This completely cured my herniated disc pain.”

The FDA’s Center for Food Safety and Applied Nutrition (CFSAN) conducts a digital audit and issues a formal FDA Warning Letter. The agency notifies the manufacturer that by curating, hosting, and using those customer testimonials in commercial promotion, the company has adopted those statements as “labeling” under 21 U.S.C. § 321(m). Because the testimonials claim to cure, mitigate, or treat rheumatoid arthritis and spinal pathology, the supplement is declared an unapproved new drug under 21 U.S.C. § 355(a) and a misbranded drug under 21 U.S.C. § 352(f)(1). The company is ordered to purge all disease-related testimonials within fifteen working days or face federal seizure and permanent injunction.

C. The “40 Years of Research” Daubert / Mohan Collapse

During an enforcement proceeding brought by the Competition Bureau under Section 74.01(1)(b) of the Competition Act, a supplement vendor attempts to prove that its joint-relief claims are supported by an “adequate and proper test.” Corporate counsel submits a binder containing 35 published scientific papers spanning forty years regarding New Zealand green-lipped mussel (Perna canaliculus).

The Bureau’s expert pharmacologist audits the 35 studies and testifies on a Mohan voir dire that:

Twelve of the studies were veterinary trials conducted on dogs and horses;
Ten of the studies were in vitro laboratory assays where concentrated lipid extracts were applied directly to isolated rat cells in petri dishes;
Nine of the human studies tested $1,500\text{ mg}$ to $3,000\text{ mg}$ per day of freeze-dried whole mussel powder, which has a completely different biochemical profile than the vendor’s $100\text{ mg}$ lipid-only oil extract; and
The remaining four human studies showed no statistically significant difference ($p > 0.05$) between the extract and the olive oil placebo on primary pain endpoints.

The Competition Tribunal strikes the vendor’s scientific defense in its entirety. Applying Canada (Competition Bureau) v. Chatr Wireless Inc., the Tribunal rules that piling up forty years of non-equivalent, animal, or statistically failed studies does not constitute an “adequate and proper test.” The vendor lacked prior scientific substantiation matching the actual dosage and formulation sold to Canadian consumers, resulting in maximum Administrative Monetary Penalties (AMPs).

Regulatory Notes / Case Law

Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 321(g)(1)(B) & § 355(a): Defining “drugs” to include articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and prohibiting the introduction into interstate commerce of any new drug without an effective FDA New Drug Application (NDA).
Dietary Supplement Health and Education Act of 1994 (DSHEA) & 21 C.F.R. § 101.36(c): Establishing the U.S. regulatory framework for dietary supplement nutrition labeling, including the specific parameters and predominance rules governing “proprietary blends.”
Food and Drugs Act, R.S.C. 1985, c. F-27, Section 3 & Section 9(1): Prohibiting the advertising of any food, drug, cosmetic, or device to the general public as a treatment, preventative, or cure for any of the diseases, disorders, or abnormal physical states referred to in Schedule A.1, and prohibiting labeling or advertising a product in a manner that is false, misleading, or deceptive or is likely to create an erroneous impression regarding its character, value, quantity, composition, merit, or safety.
Natural Health Products Regulations, SOR/2003-196, Section 93: Requiring Canadian natural health product labels to explicitly disclose the quantitative amount of each medicinal ingredient per dosage unit, preventing the concealment of active ingredient weights inside aggregate blends.
Competition Act, R.S.C. 1985, c. C-34, Section 74.01(1)(b): Prohibiting representations to the public in the form of a statement, warranty, or guarantee of the performance, efficacy, or length of life of a product that is not based on an adequate and proper test, placing the burden of proof directly on the person making the representation.
United States v. Lane Labs-USA Inc., 427 F.3d 219 (3d Cir. 2005): Landmark federal appellate authority confirming that when a supplement marketer promotes its products using third-party articles, testimonials, or research claiming to treat disease, the products are legally transformed into unapproved new drugs subject to permanent injunction and restitution.
R. v. Mohan, [1994] 2 S.C.R. 9 & Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993): The governing Canadian and American standards for the admissibility of expert scientific evidence, requiring that expert pharmacological and clinical testimony be grounded in reliable, peer-reviewed, and directly applicable scientific methodology.

nota bene: Mr. Kevin A. McLean (BA, JD, CIM) will hyperlink

Internal Links (Referrals to Other Blogs, Pages, Posts)

nota bene: Mr. Kevin A. McLean (BA, JD, CIM) will hyperlink

Smart Legislation: Law for a Digital Age (https://lawcap.ca/smart-legislation-law-for-a-digital-age/)
Deconstructing the Omega XL Marketing Architecture: Legal Boundaries of Supplement Claims (Part 1 of 3)
Supplement Subscriptions and Dark Patterns: Legal Remediation for Auto-Ship Financial Traps (Part 3 of 3)
Evaluating Content Completeness for AI Scanners Part 2: Variable Gaps, Material Omission Liabilities, and Regulatory Scrutiny (Part 2 of 3)
The Public-Sector Evidence Vitiation Standard: Exposing Regulatory Bad Faith in Algorithmic Screening Audits (Part 3 of 3)
Coram Non Judice: The Absolute Jurisdictional Nullity of State Overreach

External Authoritative Links

nota bene: Mr. Kevin A. McLean (BA, JD, CIM) will hyperlink

U.S. Food and Drug Administration (FDA) – Inspections, Compliance, Enforcement, and Criminal Investigations (Warning Letters Database)
Electronic Code of Federal Regulations (eCFR) – 21 C.F.R. § 101.36 (Nutrition Labeling of Dietary Supplements)
Health Canada – Natural and Non-prescription Health Products Directorate (NNHPD) Evidence for Homeopathic and Natural Health Products Guidance
Competition Bureau Canada – Deceptive Marketing Practices Digest: Substantiating Performance Claims
National Institutes of Health (NIH) – Office of Dietary Supplements: Omega-3 Fatty Acids Fact Sheet for Health Professionals

FAQ Section

What is a “proprietary blend” on a supplement label, and why is it controversial? Under U.S. FDA regulations (21 C.F.R. § 101.36(c)), a “proprietary blend” allows a supplement manufacturer to list a collection of ingredients under a single combined weight without revealing the exact milligram amount of each individual ingredient. While intended to protect trade secrets, consumer advocates and litigators note that it is frequently used to hide the fact that a capsule contains mostly cheap filler oils (like olive oil) and only trace, sub-therapeutic amounts of the expensive active extract advertised on television.

How does Canadian labeling law differ from U.S. law regarding proprietary blends? In Canada, under the Natural Health Products Regulations administered by Health Canada, dietary supplements (classified as Natural Health Products) cannot hide active dosages inside a proprietary blend. To receive a mandatory Natural Product Number (NPN), the manufacturer must list the exact quantitative milligram or microgram weight of every single medicinal ingredient on the label, while non-medicinal fillers (like olive oil) must be listed separately.

What triggers an FDA Warning Letter for a dietary supplement company? The FDA issues a Warning Letter when a supplement company makes claims in its advertising, website copy, social media, or customer testimonials that cross the line from “structure/function” support (e.g., “supports joint mobility”) into diagnosing, curing, mitigating, or treating a disease (e.g., “relieves arthritis pain” or “replaces prescription anti-inflammatory drugs”). Making disease claims legally reclassifies the supplement as an illegal, unapproved new drug.

Why doesn’t citing “40 years of research” protect a supplement company in court? In deceptive advertising litigation under the FTC Act or the Canadian Competition Act, scientific studies cited by an advertiser must match the exact product being sold. If the “40 years of research” involved testing massive $2,000\text{ mg}$ doses of raw green-lipped mussel powder, or involved petri-dish and animal studies, those studies are legally worthless to prove that a tiny capsule containing $50\text{ mg}$ of oil extract works in humans. Courts reject this tactic as the fallacy of “borrowed science.”

How much EPA and DHA do clinical studies actually require to reduce inflammation? According to clinical rheumatology guidelines and the National Institutes of Health (NIH), achieving a measurable, therapeutic anti-inflammatory effect from marine omega-3 fatty acids generally requires a daily dosage of $2,000\text{ mg}$ to $4,000\text{ mg}$ ($2\text{ to }4\text{ grams}$) of combined $\text{EPA}$ and $\text{DHA}$. Consumers paying premium prices for miniature marine oil capsules often receive only a tiny fraction of the omega-3 fatty acids found in a standard, inexpensive pharmacy fish oil softgel.

Law Cap Value Proposition

Law Cap Inc. (part of the “Search & Seizure Law Group Of Companies”) is a specialized legal‑forensics and digital analysis platform dedicated to sophisticated litigation strategy, constitutional oversight, and advanced asset tracking. Led by an editor with cross‑disciplinary expertise in law, securities, and behavioral psychology, Law Cap Inc. conducts high‑level blockchain forensics (including EVM‑network parsing), complex fraud analysis, metadata manipulation verification, and forensic document examination. The platform provides unrepresented litigants, counsel, and organizations with advanced, on a pro bono publico basis, analytical frameworks for navigating institutional overreach, administrative complexity, and regulatory terrain.

Law Cap exposes the strategic vulnerabilities of the administrative state. When federal tribunals attempt to weaponize silence, misdirection, and procedural delay to shield their actions from judicial review, LawCap provides the precise tactical blueprints to break the blockade. We translate complex prerogative remedies like structural mandamus, the prohibition against bootstrapping, and the doctrine of spoliation into actionable, high-impact legal strategy. By insisting on absolute algorithmic and statutory compliance. By insisting on absolute algorithmic and statutory compliance with the Federal Courts Rules, LawCap ensures that the foundational digital evidence—the raw truth of state action—is relentlessly extracted from the shadows and placed under the uncompromising scrutiny of the courts.

About the Founder, Owner, Executive Chair and CEO

Mr. Kevin A. McLean (B.A., J.D., CIM) (he/him) established Law Cap Inc. (“LawCap”) as a global platform for legal strategy, constitutional advocacy, and digital forensics. Operating within Ontario, Mr. McLean utilizes his background as a former barrister and solicitor in British Columbia, alongside credentials as a Chartered Investment Manager with the world famous and accredited Canadian Securities Institute located in Toronto, Ontario (Wellington West Avenue) (having passed in the span of eight months (eight multi-hour exams and ten if including the “mutual funds course” (see: infra): (i) the Canadian Securities Course: (ii) Wealth Management Essentials (with tax compendium modules); (iii) Investment Management Techniques; and (iv) Portfolio Management Techniques (along with although not required for the designation, the (v) the mutual funds course), to apply a broad and deep based analytical approach to Charter rights litigation and administrative accountability.

His background (the grind and lucky as they come)

Raised between the oceanfront calm of Spanish Banks in Vancouver and the warmth of Barbados, Mr. McLean grew up with a global perspective shaped by contrast — privilege without entitlement, exposure without complacency. The only father he knew, Mr. John Nugent (BA, JD, MBA, CFA Level I), legally adopted him at age nine (although ‘introduced’ at age three), marking Mr. McLean’s first direct encounter with litigation involving an absentee biological parent (father). He remains grateful to Mr. Jim Schuman, QC (as he then was), whose guidance during that process left a lasting impression on him.

Learning from the best through “osmosis” like a sponge in the Caribbean Sea

Living in Barbados part of each year throughout the 1980s and 1990s — never fully realizing how fortunate he was — Mr. McLean was introduced early to concepts such as trusts, tax residency requirements, capital gains, seed capital, convertible debentures, preferred shares, and other foundational elements of financial architecture. As his father often reminded him, “Education gets the foot in the door, but you learn and grow by doing — and you are either getting better or getting worse.”

Before his foray into junior mining on the West Coast — a sector many affectionately referred to as the “Wild West” — — Mr. Nugent served as President of Gardiner Group Stock Inc., where he managed more than 4,000 stock brokers, investment advisors, money managers, and analysts prior to the firm’s acquisition by TD Bank (a detail Mr. McLean now finds somewhat ironic). It was during this period that Mr. Nugent met Mr. McLean’s mother, then a stock broker and now a highly accomplished, world‑renowned professor and philanthropist with a Ph.D. The greatest compliment Mr. McLean has ever received came from Mr. Nugent himself, who once told him: “The best talker, salesman, and charismatic person I have ever seen. If he gets some substance, it will be a dangerous package in the real world.” Therein, the seeds of a dangerous truth-telling was born. Refinement and maturity were late blooming qualities – admittedly so.

Educational and Athletic Blessings: the infrastructure to form the public interest litigator

Mr. McLean was privileged and blessed to have attended the prestigious St. George’s School in Vancouver for both elementary and high school. When he realized that his then‑dream of representing Canada in a singular sport was becoming a reality, he transitioned to the Sports and Arts Program at Magee Secondary School, where he could begin classes an hour early and avoid elective and physical‑education requirements. This structure allowed him to train at an elite level, ultimately reaching number two in Canada in the U18 division and competing globally as a member of the Canadian National Tennis Team. He graduated from Magee Secondary School as the top student, earning the Principal’s List distinction with a 4.0 GPA in all courses.

Mr. Kevin A. McLean (BA, JD, CIM) carries on the Spanish Banks (Vancouver) running excellence tradition into the field of law nationwide (Canadian Bar Association 5 KM race)

While running a 15‑minute 5K at age 30 in the Canadian Bar Association race was an immense athletic accomplishment, Mr. McLean cherishes it most because he felt he was protecting the turf where his father had given him the privilege of growing up. His second most cherished athletic memory was winning the five‑kilometre race for the entire high school in Grade 9.

His earliest remains hitting two free throws with one second left — down by one — in Grade 7 to win the Vancouver city championship for St. George’s against St. Patrick’s. His earliest remains hitting two free throws with one second left — down by one — in Grade 7 to win the Vancouver city championship for St. George’s against St. Patrick’s.

The “McLean Name”: from the Highlands of Scotland and ode to William Wallace

The McLean name is Scottish, carried forward from Mr. McLean’s grandfather, Mr. Angus Alexander McLean, P. Eng. — the source of Mr. McLean’s middle name. Angus was married to Mrs. Margaret McLean, once the top tennis player in Canada in the 1940s and an accomplished field‑hockey athlete. She tragically passed away from cancer before Mr. She tragically passed away from cancer before Mr. McLean could meet her, though he has always understood why sport came naturally to him — the long stride, the biomechanics, and the competitive instinct. Angus suffered from macular degeneration, leaving him fully blind at age 60, and later Parkinson’s disease. He passed away in 2002, but Mr. McLean visited him every summer in Salmon Arm (having been born in Smithers, B.C.), often accompanied by his paternal grandmother, Ms. McLean visited him every summer in Salmon Arm (having been born in Smithers, B.C.), often accompanied by his paternal grandmother, Ms. Helen Elizabeth Lane (née Allsop), a pilot well into her 80s who passed away in 2012 and remains his favourite woman of all time. Mr. McLean often reflects on his grandfather’s resilience, noting: “I never heard him complain once — and if we could all be so grateful to be alive.” Through an eccentric yet uniquely detailed family tree, Mr. McLean learned that the McLean surname traces back to the 1300s in Scotland alongside none other than Sir William Wallace (later sensationalized by Mel Gibson in Braveheart). It thus became unsurprising to him why he has always been so staunchly stubborn and assertive about one’s rights, no matter the circumstance.

The Most Unique of Skill Sets at age 43 (March 25, 1983) (a “True Aries”)

Intersections of Law and Cryptography

The professional trajectory of Mr. McLean is defined by the deconstruction of unauthorized surveillance networks and the exposure of systemic irregularities.

Forensic Capabilities: His forensic data skills have frequently addressed complex anomalies within administrative and appellate contexts.
Blockchain Analysis: Following a 2014 incident involving an unauthorized RAM dump, Mr. McLean acquired proficiency in hexadecimal language to parse a one-million-page compressed architectural record.
Cross-Chain Tracking: He successfully traced unauthorized data disclosures across the Ethereum blockchain in Switzerland and EVM-compatible networks, such as the Binance Smart Chain (BSC).
Judicial Evidence: These findings provided significant blockchain evidence before the Honourable Justice Bowden of the British Columbia Supreme Court (BCSC) in December 2015 which was withheld from the BCSC (see: McLean v. Law Society of British Columbia, 2015 BCSC 661; McLean v. Law Society of British Columbia, 2015 BCSC 1431; McLean v. Law Society of British Columbia, 2015 BCSC 1972; McLean v Law Society of British Columbia, 2017 BCSC 987; Law Society of British Columbia (Re), 2018 BCIPC 37 (author was the successful unnamed respondent therein); and McLean v. Attorney General of British Columbia, 2019 BCCA 133 [defeated the AGBC at the Court of Appeal, no leave to appeal by AGBC]; and by change of legislation in 2024, the author has become the first to ever defeat in any motion, hearing and in finality a professional and regulatory association or body at all and in the field of public interest litigation involving the breach of Charter rights of members and clients of members

Adversity and Resilience

After transitioning to e-commerce ventures in the health and wellness sector in 2015, Mr. McLean navigated and is navigating as a result of CAT impairments (physical in nature but with mind-body connection) significant extralegal challenges and physical trauma.

Physical Recovery: Following a severe vehicular incident on August 31, 2022, which resulted in devastating spinal injuries, he maintains a disciplined daily regimen involving specialized orthotics and minimalist biomechanics to manage his recovery.
Procedural Strategy: Despite physical hardship, Mr. McLean utilized an extensive command of procedural law during a multi-jurisdictional detention to secure his release by demanding adherence to Criminal Code protocols, specifically Form 2 and Form 7 requirements.

Litigation and Procedural Discovery

This commitment to legal redress led to the discovery of a notable event in Canadian legal history: the post-facto falsification of a six-page “Information Package” (footer CCO-2–000-1).

Case Comparison: While historical precedents such as R. v. Silva (Quebec 2019/2020) involved the unauthorized use of a judicial stamp, the wholesale falsification of an entire six-page package is considered unprecedented.
Ongoing Oversight: Further irregularities, nullities (jurisdictional in nature) discovered involving various levels of the judiciary remain subjects of scrutiny and formal complaint.

Outside Interests: Athletics and mental health (lifelong journeys – not destinations)

Mr. Kevin A. McLean (BA, JD, CIM) has always lived life at full speed — sometimes literally. He still holds the record for the fastest five‑kilometre time ever run by a lawyer in the Canadian Bar Association’s annual 5K race, clocking an extraordinary 15:05 in one of the years he won the event. Before entering law, Kevin competed on the Canadian National Tennis Team (U16 and U18), representing Canada at the world‑renowned Orange Bowl — the largest junior tennis tournament on the planet. Winning a round there placed him among the top 20 junior players globally in his age category.

His athletic career continued at The Ohio State University, where he played NCAA tennis on scholarship beginning in 2001. To this day, Kevin remains a proud Buckeye, a donor to the university, and a familiar (or intentionally hard‑to‑find) face on eight or so College Football Saturdays each year in Columbus, Ohio. He still enjoys the tradition of “Kegs and Eggs,” though for him it’s now just the eggs — Kevin is a long‑retired drinker who speaks openly and gratefully about the role evidence‑based treatment including medication for ADHD played in transforming his life. He recommends (but does not advise) anyone struggling with any such symptoms to seek professional help from a qualified psychiatrist.

Kevin is single, unmarried, and a non‑parent — not out of absence, but out of purpose. As he likes to say, he is “married to the game,” and he believes “the public deserves it.” His work, his advocacy, and his commitment to building accessible legal knowledge platforms reflect that ethos: disciplined, service‑oriented, and driven by a sense of responsibility larger than himself.

The Philosophy of LawCap

LawCap is a movement where intellectual application and mental fortitude are prioritized over brute force. The philosophy maintains that systemic corruption is addressed through analytical capacity and a command of the law. LawCap seeks the engagement of individuals dedicated to improving society and achieving accountability through truth. Live your life within the boundaries of law and on your own terms.

GOOGLE MY BUSINESS

Contact Information and Helpful Links

Email: info@lawcap.ca and mclean@searchandseizure.ca

Confidential fax: (416) 352‑0055

Mailing address: Suite 314, 720 King Street West, Toronto, Ontario

Google My Business: LawCap Inc.

Feel free to check out our daily posts! We break the news before the so called “breaking news”! #breakthenewsbeforethebreakingnews (it is a mouthful but iron sharps iron and no pain no gain. If it was easy, everyone would be doing it. Feel free to chat with us on Google MyBusiness, email, text, call and if you are really fearful of government (and we have been there and nothing wrong with some out of an abundance of caution (ex abundanti cautela), you can confidentially fax at 1 (416) 352-0055). We honour strictly the duty of confidence found as precedent in the SCC and paying a little homage to No Limits Sportswear Inc. v. 0912139 B.C. Ltd., 2015 BCSC 1698 as per The Honourable Madam Justice S. Griffin (who in the Applicant’s estimation was and is a phenomenal judge but obviously he is most partial to The Honourable Madam Justice Gerow, The Honourable Mr. Justice Bowden, The Honourable Mr. Justice Grauer The Honourable Mr. Justice McIntosh, The Honourable Madam Justice Dickson, The Honourable Mr. Justice Masuhara, The Honourable Mr. Justice Goepel (as he then was) and The Honourable Mr. Justice Tysoe) (and oddly The Honourable Justice Matajawa as per the caselaw in LSBC v. Lawyer “A” as he found that the Applicant’s case against the LSBC involved him not consenting to any forensic copying (little did he or the Applicant know at the time that there was a Concealed RAM Dump).

Courage is contagious. A coward dies a thousands deaths but a warrior dies but one (Sir William Shakespeare). Lastly, to the extent that anything is shared via any medium, the recipient is under a strict duty of confidence and cannot be compelled to provide the same absent court order and to the extent any matter involves matters preparatory to litigation and/or ongoing litigation, it will be presumed to be protected by litigation privilege without any exceptions).

DISCLAIMER (generally)

It is strictly mandated that no constituent element of the information promulgated herein shall be erroneously construed as the provision of formal legal advisement; concurrently, the dissemination of such documentation ipso facto precludes the formation of any solicitor-client, attorney-client, or analogous professional relationship (the “Professional Relationship”). All articulated postulations, wherein they remain unanchored to demonstrable and objective empirical data, constitute the exclusive, prima facie perspectives of the underlying commercial enterprise (the “Commercial Enterprise”). Furthermore, all disseminated publications are incontrovertibly shielded by established jurisprudential defences (the “Jurisprudential Defences”), encompassing justification, fair comment promulgated strictly in good faith, and the rigorous execution of a moral, ethical, statutory, prescribed, and common law duty, coupled with recognized journalistic protections as elucidated by the Supreme Court of Canada in Grant v Torstar Corp, 2009 SCC 61 (the “Grant Decision”).

Potential Lawsuits (generally and this specific article, post or blog): Waiver of Personal Service and Cautionary Admonition

Regarding any subjective apprehension of a nascent cause of action within the jurisdiction of Ontario grounded in defamation, or any alternative tortious liability implicating this digital publication platform (the “Publication Platform”), the aforementioned commercial enterprise, or the individual proprietor, Kevin Alexander McLean, B.A., J.D., C.I.M. (the “Proprietor”, “CEO”, “Owner”, “Editor”)—who formerly practiced as a barrister and solicitor in the jurisdiction of British Columbia and maintains the professional designation of Chartered Investment Manager—it is unequivocally mandated that such grievances be addressed pursuant to the rigorous strictures of Canadian tort jurisprudence.

Should litigation be commenced against the commercial enterprise or the proprietor pertaining to allegations of defamation, irrespective of the underlying judiciousness of the antecedent legal advisement, service of process shall be accepted exclusively via electronic transmission at the previously designated electronic mailing addresses, thereby effectuating a binding waiver of the requirement for effectuating personal service. Notwithstanding this procedural concession, an unequivocal reservation of rights is maintained in limine for the explicit purpose of seeking security for costs, pursuing the summarily striking of the pleadings via summary judgment—strictly distinguished from a summary trial—and applying for elevated cost awards on a substantial indemnity or full indemnity basis against the initiating party in either a personal or corporate capacity. Furthermore, overarching rights are expressly reserved to seek interlocutory and injunctive relief, alongside the commencement of counterclaims seeking substantive damages for multifarious tortious infractions, expressly including the tort of abuse of process, and concurrently seeking remedial measures against any retained legal representatives. The prerogative to freely publish commentary delineating the procedural evolution of any such litigation, constituting public acta, is similarly and irrevocably reserved.

Given that causes of action sounding in defamation must be adjudicated before a superior court possessing inherent jurisdiction—specifically, a tribunal constituted pursuant to section 96 of the Constitution Act, 1867 (the “Section 96 Court”)—any party initiating such proceedings irrevocably attorns generally to the jurisdiction of the Province of Ontario and to that specific judicial echelon at first instance. Judicial resources remain intrinsically finite; their utilization necessitates the expenditure of the public treasury across multiple governmental strata. This encompasses the executive branch, financed by the provincial government via the taxation of the citizenry; the judicial branch, remunerated by the federal government; and tertiary municipal expenditures whereby auxiliary judicial officers are perpetually contracted through municipal law enforcement agencies, functioning effectively as a government institution (the “Government Institution”), such as the Toronto Police Services Board.

While the fundamental right to articulate dissenting opinions is rigorously respected, and electronic correspondence remains welcomed for the exclusive purpose of identifying substantive inaccuracies necessitating amelioration, it is unambiguously declared that no financial indemnification shall be disbursed, as no valid cause of action in defamation or otherwise is recognized to subsist. Consequently, should the instigation of formal litigation remain the finalized trajectory, the requisite tariff of fees must be remitted in strict accordance with the attendant regulations promulgated under the Administration of Justice Act, R.S.O. 1990, c. A.4. Subsequently, discrete copies of the formally issued—as rigidly distinguished from merely filed—statement of claim (the “Statement Of Claim”) must be concurrently served upon all respective respondents, whereupon subsequent procedural mechanisms shall be accordingly activated. Any deviation from these prescribed procedural modalities, constituting a direct contravention of statutory mandates, the equitable doctrines of fairness, or the strictures delineated within the Rules of Civil Procedure, R.R.O. 1990, Reg. 194 (the “Procedural Rules”), shall categorically not be countenanced as a remediable irregularity. Rather, such defective origination or procedural non-compliance shall be definitively construed as an absolute nullity, functioning ultra vires the initiating party’s jurisprudential authority, and effectuating a compulsory reversion to the status quo ante.

Love Finding Topics in an Efficient Manner?

Do you need any help finding a topic or tag, in addition to our encyclopedia, please click our “Legal Topics & Investigative Index” and it will assist in you finding topics, posts, blogs, and pages on that specific topic or tag: https://lawcap.ca/legal-topics-investigative-index/

Feel free to check out “No Cap” © Legal Encyclopedia ©, which is updated and grows daily: https://lawcap.ca/law-cap-inc-s-proprietary-and-trademarked-no-cap-legal-encyclopedia/#jn-a